An estimated 20–25% of the population is affected by chronic, non-communicable
inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most …

Atopic dermatitis (AD) is a chronic, inflammatory skin disorder characterized by eczematous
and pruritic skin lesions. In recent decades, the prevalence of AD has increased worldwide …

The evidence‐and consensus‐based guideline on atopic eczema was developed in
accordance with the EuroGuiDerm Guideline and Consensus Statement Development …

Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis
is made using evaluated clinical criteria. Disease activity and burden are best measured …

This guideline was developed as a joint interdisciplinary European project, including
physicians from all relevant disciplines as well as patients. It is a consensus‐based …

Atopic dermatitis (AD) is a clinically defined, highly pruritic, chronic inflammatory skin
disease of children and adults. The diagnosis is made using evaluated clinical criteria …

The existing evidence for treatment of atopic eczema (atopic dermatitis, AE) is evaluated
using the national standard Appraisal of Guidelines Research and Evaluation. The …

Atopic dermatitis is a common, chronic inflammatory dermatosis that can affect all age
groups. This evidence-based guideline addresses important clinical questions that arise in …

This parameter was developed by the Joint Task Force on Practice Parameters,
representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the …

Introduction: Dupilumab is a new treatment option for patients with moderate-to-severe
atopic dermatitis. It blocks IL-4/IL13-signaling and thereby inhibits receptor signaling …